Ipamorelin
Selective growth hormone secretagogue.
Ipamorelin
Background
Ipamorelin is a synthetic pentapeptide and selective agonist of the growth-hormone secretagogue receptor (the ghrelin receptor). It was characterized as the first GHS to stimulate growth-hormone release with high selectivity and without the elevations in cortisol, prolactin, or ACTH seen with earlier secretagogues.
The foundational pharmacology is well documented in preclinical work; ipamorelin has not advanced to an approved therapeutic indication.
Selected literature
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16(9):1412-1416.
- Andersen NB, et al. The effect of growth hormone (GH) secretagogues on bone. Journal of Endocrinology. 1999.
References are provided for scientific context only. Citation does not imply endorsement of any use, nor a claim of safety or efficacy. Findings frequently derive from in-vitro or animal models.
Trademarks & attribution
Ipamorelin (NNC 26-0161) originated from Novo Nordisk research and has no approved trademarked drug product. Catalyst Research Labs is not affiliated with Novo Nordisk. Supplied as reference material only.
